Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results

Figure 1 Overview of mean work productivity and activity impairment (WPAI) domain scores comparison vs baseline in patients employed at baseline (employed analysis population). A: Patients with absenteeism; B: Patients with presenteeism; C: Patients‘ work impairment; D: Patients’ activity impairment. Bars represent the standard deviation. A significant reduction in all work productivity and activity impairment sub-scores after onset of golimumab therapy was detectable for each time point in comparison to baseline (for each visit P < 0.0001, Wilcoxon signed rank test). UC: Ulcerative colitis; BL: Baseline; n: Number of patients; SD: Standard deviation.